SCHEMBL24007902

SCHEMBL24007902

CC(C)n1nc(Cl)cc(NC(=O)C(C)(C)C)c1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 3/20 0.41
▸ HPGD P15428 2/20 0.41
▸ MITF O75030 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ KLF5 Q13887 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ TDP1 Q9NUW8 1/20 0.41
▸ GAA P10253 1/20 0.36
▸ HTT P42858 6/20 0.35
▸ MALT1 Q9UDY8 1/20 0.35
▸ POLB P06746 1/20 0.35
▸ BRPF1 P55201 1/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ RAB9A P51151 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ L3MBTL1 Q9Y468 1/20 0.34
▸ CETP P11597 1/20 0.34
▸ MAPT P10636 3/20 0.33
▸ LMNA P02545 2/20 0.33
▸ LCK P06239 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24007634 0.81 KDM4E (0.44) KDM4EHPGDMITFALDH1A1KLF5
SCHEMBL24007919 0.79 TMIGD3 (0.43) KDM4EHPGDMITFALDH1A1KLF5
SCHEMBL24567209 0.70 KDM4C (0.36) KDM4EHPGDMITFALDH1A1KLF5
SCHEMBL24567228 0.70 KDM4C (0.36) KDM4EHPGDMITFALDH1A1KLF5
SCHEMBL24567215 0.69 KDM4E (0.35) KDM4EHPGDMITFALDH1A1KLF5
SCHEMBL18383188 0.68 ALDH1A1 (0.43) KDM4EHPGDMITFALDH1A1KLF5
SCHEMBL18387539 0.68 L3MBTL1 (0.42) KDM4EHPGDMITFALDH1A1KLF5
SCHEMBL18260522 0.65 KDM4E (0.39) KDM4EHPGDMITFALDH1A1KLF5
SCHEMBL29565434 0.65 KDM4E (0.39) KDM4EHPGDMITFALDH1A1KLF5
SCHEMBL17323697 0.65 KDM4E (0.39) KDM4EHPGDMITFALDH1A1KLF5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230265075-A1 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS AJAX THERAPEUTICS, INC. 2023-08-24 — — US disclosed
US-20230265075-A1 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS AJAX THERAPEUTICS, INC. 2023-08-24 — — US disclosed
US-11691963-B2 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors AJAX THERAPEUTICS, INC. (US) 2023-07-04 — — US disclosed
US-11691963-B2 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors AJAX THERAPEUTICS, INC. (US) 2023-07-04 — — US disclosed
US-20220411403-A1 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS AJAX THERAPEUTICS, INC. 2022-12-29 — — US disclosed
WO-2021226261-A1 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS AJAX THERAPEUTICS, INC. (US) 2021-11-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220411403-A1 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS JAK2, JAK3, STAT5B KDM4E 444/4885HPGD 3069/4885MITF 1560/4885
US-20230265075-A1 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS JAK2, JAK3, STAT5B KDM4E 444/4885HPGD 3069/4885MITF 1560/4885
US-11691963-B2 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors JAK2, JAK3, STAT5B KDM4E 444/4885HPGD 3069/4885MITF 1560/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback